Integrin avb6 is a heterodimeric cell surface receptor, which is absent from the normal epithelium, but is expressed in wound-edge keratinocytes during re-epithelialization. However, the function of the avb6 integrin in wound repair remains unclear. Impaired wound healing in patients with diabetes constitutes a major clinical problem worldwide and has been associated with the accumulation of advanced glycated endproducts (AGEs) in the tissues. AGEs may account for aberrant interactions between integrin receptors and their extracellular matrix ligands such as fibronectin (FN). In this study, we compared healing of experimental excisional skin wounds in wild-type (WT) and b6-knockout (b6 ) ⁄ ) ) mice with streptozotocin-induced diabetes. Results showed that diabetic b6 ) ⁄ ) mice had a significant delay in early wound closure rate compared with diabetic WT mice, suggesting that avb6 integrin may serve as a protective role in re-epithelialization of diabetic wounds. To mimic the glycosylated wound matrix, we generated a methylglyoxal (MG)-glycated variant of FN. Keratinocytes utilized avb6 and b1 integrins for spreading on both non-glycated and FN-MG, but their spreading was reduced on FN-MG. These findings indicated that glycation of FN and possibly other integrin ligands could hamper keratinocyte interactions with the provisional matrix proteins during re-epithelialization of diabetic wounds.
Diabetes mellitus affects approximately 170 million people worldwide, and this number is projected to double by the year 2030 (1) . Diabetes has been associated with a number of physiologic factors that predispose to aberrant wound healing, such as impaired growth factor production (2-4), angiogenic response (4, 5) , macrophage function (6) , collagen accumulation, epidermal barrier function, quantity of granulation tissue (4), keratinocyte and fibroblast migration and proliferation (7) , and synthesis of ECM components and their remodeling by matrix metalloproteinases (MMPs) (8) . In addition, a prolonged state of systemic hyperglycemia is an important factor for the molecular pathophysiology of diabetic complications because of the gradual build-up of advanced glycated endproducts (AGEs) in the tissues. AGEs are formed by an irreversibly, non-enzymatic reaction between the amino groups of tissue proteins, such as collagen and fibronectin (FN) in the extracellular matrix (ECM), and reducing sugars, which are abundant in hyperglycemia (9) . These modifications of the ECM proteins alter cell-ECM interactions, including cell adhesion and migration that are critical for wound healing (9) . It is likely that the changes are mediated by aberrant interactions of the glycated ECM proteins with the cell surface receptors of the integrin family.
Integrins are heterodimeric, transmembrane receptors that consist of an a and a b subunit (10) (11) (12) . Through specific interactions with ECM proteins, integrins mediate cell adhesion, migration, proliferation and survival of many cell types, including keratinocytes (13, 14) . During wound healing, keratinocyte integrins regulate wound re-epithelialization (14, 15) . Many integrins recognize a specific conserved tri-peptide motif, arginine-glycine-asparagine (RGD), which is found in a variety of ECM proteins such as FN, vitronectin, and tenascin-C (16, 17) . In cell cultures, the expression of keratinocyte-specific avb6 integrin facilitates keratinocyte adhesion and migration on the early wound provisional matrix (18, 19) . Furthermore, the avb6 integrin activates transforming growth factor (TGF)-b1, an important molecule that promotes wound re-epithelialization by binding to the latent TGF-b complex (20, 21) . In fact, avb6 integrin may be critically important for TGF-b1 bioactivity in vivo (22) . Studies of acute wound healing in young b6 integrin-deficient mice (b6 ) ⁄ ) ) and b6 integrin over-expressing mice did not detect any abnormalities in the healing of experimental skin wounds (23, 24) , suggesting that this integrin may not be necessary for normal wound healing. In contrast, in mice where wound healing was compromised by corticosteroid-induced immunosuppression or by old age, b6 integrin deficiency resulted in delayed wound healing (25) . In diabetic ulcers, wound closure is delayed or lacking as a result of reduced epithelial migration. In addition, the level of TGF-b in diabetic wounds is reduced compared with non-diabetic wounds (26) . Therefore, we hypothesized that avb6 integrin plays a role in compromised wound healing associated with the diabetic state. To this end, we examined the role of avb6 integrin in wound healing in adult mice in which diabetes was induced by intraperitoneal injections of streptozotocin (STZ). Furthermore, we investigated the effects of glycation of the provisional wound matrix protein FN on integrin-mediated adhesion of human skin keratinocytes.
MATERIALS AND METHODS

Animals
The animal studies were conducted in compliance with the Canadian Council on Animal Care (CACC) and approved by the University of British Columbia Animal Care Committee. Forty-eight 12-to 14-month-old male wild-type (WT) FVB and age-and sex-matched b6 ) ⁄ ) mice with the same genetic background were used in this study (generous gift from Dr. Dean Sheppard, University of California, San Francisco). Each experimental group was subdivided into STZ-treated (WT: n = 14; b6 ) ⁄ ) : n = 15) and vehicle-treated control groups (WT: n = 9; b6
: n = 10).
Streptozotocin induction of diabetes in mice
Mice were maintained under fasting conditions for 4 h and subsequently anesthetized with a mixture of isoflurane and oxygen. After induction of anesthesia, mice in the experimental group received peritoneal injections of STZ (55 mg ⁄ kg of body weight; Sigma Aldrich Inc., St. Louis, MO, USA) in citrate buffer (P-4809; Sigma Aldrich Inc.). Animals in the control group were injected with an equivalent volume of citrate buffer only. This treatment was carried out for six consecutive days. Tail blood samples were collected on a weekly basis from fasting animals and analyzed for serum glucose level using the Accuchek Ò system (Roche Diagnostics, F. Hoffmann-La Roche Ltd, Basel, Switzerland) to verify successful development of experimental diabetes in the STZtreated animals. A serum glucose concentration exceeding 17 mmol ⁄ L was considered to reflect the onset of diabetes (27, 28) .
Experimental wounds
Animals were anesthetized as described above, and the dorsal skin was shaved and depilated (VeetÔ; Reckitt-Benckiser, NA Inc., Parsippany, NJ, USA). Four full-thickness, 4-mm excisional wounds were created on the dorsal skin of each mouse using a sterile, disposable biopsy punch (Miltex, Inc., York, PA, USA). After wounding, mice were maintained in separate cages and had access to food and water ad libitum.
To assess the rate of wound healing, images of all wounds were recorded at the time of wounding (day 0) and on a daily basis post-wounding using a digital camera (Nikon Coolpix 995; Nikon, Tokyo, Japan). All wound pictures were standardized according to a measurement ruler included in the images. The wound surface areas were quantified using the NIH ImageJ program (National Institute of Health; http:// rsb.info.nih.gov/ij/), and the healing was expressed as a percentage of the initial wound area on day 0.
A total of n = 36-56 wounds per group were analyzed from each time point.
Histologic and immunohistochemical examination of wounds
For histologic and immunohistochemical analyses, tissue biopsies were obtained from the wound sites on days 5 and 10 after wounding. To this end, mice were euthanized by CO 2 inhalation and wound biopsies containing the complete wounded area as well as adjacent wound margin and normal skin were harvested using a 6-mm sterile biopsy punch. The tissue samples were mounted in Tissue-TEK (Sakura, Torrance, CA, USA) and snap-frozen on dry ice immediately after collection. Frozen sections (6 lm) were prepared and stored at )80°C until use. For orientation and to localize mid-wound sections, every tenth slide was stained with Harris' hematoxylin and eosin (H&E). Only the mid-wound sections were used for comparative analyses. Epithelial gap distance was measured as the distance between epithelial tongues in the wound cross-sections using NIH ImageJ, and histology was scored from 1 (lowest) to 4 (highest) based on previously used criteria (29) . A subset of 5-day-old wounds was fixed with 10% buffered neutral formalin and stained using a modified Movat's pentachrome staining procedure. Briefly, the fixed sections were placed in Alcian blue dye overnight and rinsed in running water for 5 min. The sections were then soaked in warm (60°C) alkaline alcohol for 60 min, followed by the standard staining procedure as described previously (30) . Histologic assessment of granulation tissue formation used an ordinate scale from 1 to 4 reflecting the degree of density and organization of neo-synthesized collagen fiber bundles as low (1), medium (2), or high (3). The presence of mature collagen among well-granulated wounds yielded a score of 4. All histologic scoring was performed in a blinded manner, evaluating n = 5-6 wounds (two sections per wound) from five to six mice per group.
For the detection of avb6 integrins in experimental and control wounds, frozen sections were fixed for 5 min with acetone pre-cooled to )20°C, rinsed with phosphate-buffered saline (PBS; 137 mM NaCl, 2.7 mM KCl, 10 mM Na 2 HPO 4 , 2 mM KH 2 PO 4 in distilled water, pH 7.4) containing 1 mg ⁄ mL bovine serum albumin (BSA; Sigma Aldrich Inc.), and incubated with normal blocking serum (Vectastain; Vector Laboratories, Burlingame, CA, USA) at room temperature for 30 min. For detection of avb6 integrin, sections were incubated with rabbit anti-human monoclonal antibody b6B1 (a generous gift from Dr. Dean Sheppard, University of California, San Francisco, CA) diluted 1:10 dilution in PBS containing 1 mg ⁄ mL BSA in a humidified chamber at 4°C overnight. After washing with PBS ⁄ BSA, sections were first incubated with an anti-rabbit biotinylated secondary antibody for 60 min at room temperature, and then with Vectastain Ò ABC reagent (Vectastain Ò Elite Kit) according to the manufacturer's guidelines. The reaction was visualized using the VIP (purple stain) substrate kit. The primary antibody was omitted in the negative controls, none of which showed positive staining.
Glycation of fibronectin with methylglyoxal
Fibronectin was purified from human plasma by gelatin-Sepharose affinity chromatography according to established procedures (31) . Briefly, plasma was diluted in chromatography buffer (50 mM Tris; 0.15 M NaCl, pH 7.4) and particulate matter was sedimented by centrifugation at 2500 g for 20 min. The supernatant was loaded on a gelatin-Sepharose affinity column (GE Healthcare Bio-sciences AB, Uppsala, Sweden). After extensive washes with chromatography buffer alone, non-specifically bound proteins were removed with buffer containing 1 M NaCl. Gelatin-binding MMP-2 and MMP-9 were eluted with 2% DMSO and bound FN was eluted with 3 M urea in chromatography buffer (32) . Elimination of MMP-2 and -9 was verified by gelatin enzymography using 10% SDS-PAGE gels copolymerized with heat-denatured type I collagen (33, 34) . Purified FN was quantified using the BCA assay (Pierce, Rockford, IL, USA), frozen slowly, and stored at )80°C until analysis. For glycation, purified human FN (866 lg ⁄ mL) was incubated with 67 mM methylglyoxal (MG; Sigma Chemical Co., St. Louis, MO, USA) in PBS. The native FN control was diluted to the same concentration in PBS without MG. Both MG-treated and control FN were dialyzed against PBS for the same periods of time (9) . To confirm the conjugation of MG to FN molecules, an affinity-purified rabbit anti-MG-AGE polyclonal antibody (kindly provided by Dr. Shamsi, University of Cleveland, OH) (35) was used as a probe. Glycated FN and untreated control samples were separated with 7.5% SDS-PAGE gels under reducing conditions (65 mM dithiothreitol) and then transferred to polyvinylidene difluoride membranes (Millipore Corp., Bedford, MA, USA). The membranes were blocked with 10 mg ⁄ mL heat-denatured BSA in 50 mM Tris, pH 7.4, at 37°C for 60 min, and then incubated with rabbit anti-MG-AGE at a 1:2000 dilution in 20 mM Tris ⁄ 150 mM NaCl ⁄ 0.1% Tween 20 buffer (pH 7.4) containing 1% (w ⁄ v) BSA at 4°C overnight. The MG-treated protein was detected with a horseradish peroxidase-conjugated goat anti-rabbit antibody (IgG H+L) at a 1:5000 dilution in PBS ⁄ Tween containing 5 mg ⁄ mL BSA, followed by chemiluminescence reagent (PerkinElmer LAS, Inc., Boston, MA, USA) for 1 min. The image was captured using 
Plate-binding assay for coating efficiency
To determine whether FN and FN-MG were coated with the same efficiency, the proteins were incubated in 96-well plates at identical, serially diluted concentrations from 2 to 0.002 lg ⁄ well in 0.1 M NaHCO 3 ⁄ Na 2 CO 3 (pH 9.6) at 4°C overnight. Heat-denatured BSA (10 mg ⁄ mL) in 50 mM Tris buffer (pH 7.4) was used to block non-specific binding sites by incubating for 1 h at 22°C. After thorough washing with 50 mM Tris buffer containing 0.05% (v ⁄ v) Tween 20, plates were incubated with a polyclonal rabbit anti-FN antibody (36) for 60 min at 22°C. Bound proteins were detected by incubating with alkaline phosphataseconjugated goat anti-rabbit IgG (1:1000 dilution; Bio-Rad Laboratories) for 1 h at 22°C. After several rinses, 1 mg ⁄ mL phosphatase substrate (Sigma Aldrich Inc.) was added to the wells. The reactions were quantified at 405 nm using an Opsys MR plate reader (Dynes, Chantilly, VA, USA).
Cell spreading assay
A 48-well culture plate (Falcon MultiwellÔ; BD Biosciences, Franklin Lakes, NJ, USA) was coated with 5, 20, or 50 lg ⁄ mL FN or FN-MG diluted in PBS containing Ca 2+ and Mg 2+ and incubated for 1 h at room temperature. Wells were then blocked with 1% heat-denatured BSA in PBS for 30 min at room temperature and subsequently washed twice in PBS. Sub-confluent human skin HaCaT keratinocytes (a generous gift from Dr. Fusenig, German Cancer Center, Heidelberg, Germany) were seeded at 2.0 · 10 4 cells per well in serum-free Dulbecco's modified Eagle's medium (Flow Laboratories, Irvine, UK) supplemented with 23 mM Na 2 CO 3 , 20 mM Hepes (GibcoÔ; Invitrogen Corporation, Carlsbad, CA, USA), antibiotics (50 lg ⁄ mL streptomycin sulfate and 100 U ⁄ mL penicillin; Sigma Aldrich, Inc.), 10% heat-inactivated fetal bovine serum (Gibco Life Technologies), and 50 lM cycloheximide (Sigma Aldrich, Inc.) to prevent de novo protein synthesis. Cells were incubated for 45 min to 3 h at 37°C in the presence of 5% CO 2 to allow cell spreading. At indicated time points, the experiment was terminated by the addition of appropriate volume of 2· cell fixative (8% formaldehyde, 10% sucrose in PBS). The wells were then filled with distilled water to the top and covered with a glass plate for analysis. Cells with a ring of lamellar cytoplasm were considered spread. Cell spreading was quantified using a phase-contrast microscope (Nikon TMS; Nikon) equipped with a grid-eyepiece as detailed previously (19) . Briefly, the number of cells showing spreading in four randomly selected fields from each of three replicate wells was counted, and cells that were surrounded by a ring of lamellar cytoplasm were considered spread.
Blocking of integrin function
Cells were seeded at 1.0 · 10 4 cells per well in 96-well plates (Nunc, Roskilde, Denmark) coated with FN or FN-MG as in the presence or absence of monoclonal antibodies with the capacity to specifically block the functions of the b1 [mAb13; 20 lg ⁄ mL (37)], av (L230; 20 lg ⁄ ml), or b6 [10D5; 50 lg ⁄ ml (38)] integrin subunits. Antibody L230 was purified from culture supernatants of hybridoma cells (ATCC HB8448) in our laboratory. All antibody concentrations used were previously optimized to produce maximal inhibition of cell spreading (data not shown). The cells were incubated with the anti-integrin antibodies for 15 min on ice prior to seeding and transfer to the cell culture incubator (5% CO 2 ; 37°C) for cell adhesion and spreading. When about 50% of cells without inhibitory antibodies showed spreading, all cells were fixed and cell spreading was quantified.
Statistical analysis
A Student's t-test (two-tailed, Bonferroni-adjusted) was used to assess pairwise differences in wound healing kinetics between each day of healing, whereas epithelial gap distances from mid-wound H&E sections were analyzed using a Mann-Whitney U-test (GraphPad Prism 5.0; GraphPad Software, Inc., La Jolla, CA, USA). For all cell spreading experiments, we used a two-way ANOVA with Bonferroni post-test to describe differences between cell behavior on native vs glycated FN for various concentrations of FN, time, and anti-integrin antibody blockings. A p-value less than 0.05 was considered statistically significant.
RESULTS
STZ induction of experimental diabetes
For six consecutive days beginning on day 50 prior to generating experimental wounds, adult FVB WT and b6 integrin knockout mice were treated intraperitoneally with STZ to induce pancreatic b-cell autoimmunity and a chronic state of systemic hyperglycemia. During these 50 days, we observed an insignificant loss of animals in the control group, but considerable losses among the diabetic animals, especially in the b6 ) ⁄ ) group (Fig. 1A) . Blood glucose measurements (Fig. 1B,C) , each time taken after 4 h of fasting, showed that a glucose concentration above 17 mmol ⁄ L reflecting a diabetic state (27) was achieved within the first 2 weeks of STZ treatment for both FVB and b6 ) ⁄ ) mice. A steady state of severe hyperglycemia (25-30 mmol ⁄ L) developed approximately 10 days prior to wounding in STZ-treated animals, whereas all control mice maintained normal blood glucose levels of 10-11 mmol ⁄ L throughout the study period. Body weights (Fig. 1D,E) decreased only in the diabetic populations, a clinical sign of impaired glucose uptake. Mice in the b6 ) ⁄ ) group had lower body weights compared with their FVB WT littermates. Tail neuropathy was consistent with a state of chronic hyperglycemia (Fig. 1F,G) .
Wound healing kinetics
To evaluate the contribution of b6 integrin to wound repair in normal and diabetic mice, we first quantified clinical wound healing from digitized images. A representative panel is shown from day 0, 5, and 10 from all four experimental groups ( Fig. 2A) . The final sample consisted of 36-56 wounds per experimental group. Changes in size of wound areas are presented in Fig. 2B -F. Wounds in the control groups were closed by day 7 with no difference in healing rates between the WT and b6 ) ⁄ ) mice (Fig. 2B) . In comparison, among the diabetic animals, b6
) ⁄ ) mice showed a small but significant delay in wound healing from day 1 to 3 compared with WT, but no other differences were observed and complete wound closure was reached on day 9 (Fig. 2C) . Induction of diabetes in the WT animals caused a small but significant delay in wound healing on days 3 and 4 (p < 0.05), and the wounds closed at the same time as WT animals without diabetes (Fig. 2D) . Finally, the diabetic b6 ) ⁄ ) mice exhibited approximately a whole day delay in wound healing compared with b6 ) ⁄ ) mice without diabetes. The difference was statistically significant from day 1 to day 6 (Fig. 2E) . The combined effects of the b6 knockout and the diabetic state resulted in an overall delay in wound closure of nearly 2 days compared with the WT mice (Fig. 2F ).
Histology and immunohistochemistry
Histologic staining of 5-day-old wound specimens (Fig. 3A) confirmed the clinical woundhealing data with a significant difference in epithelial gap distance between control and diabetic animals (p < 0.01). Deficiency of b6 integrin did not lead to increased epithelial gap distance in normal wound repair (p = 0.578), but was more influential in diabetic wound healing, yet statistically insignificant at day 5 (p = 0.112) (Fig. 3B) . In concordance with these observations, histologic scoring at day 5 showed no difference among the control animals, but a reduced score for the diabetic animals, and in particular, the b6 integrin-deficient group (Fig. 3C) . The Movat's modified pentachrome staining was carried out on a set of day 5 wounds to assess the formation of granulation tissue and collagen deposition (Fig. 4A) . The wounds in the control animals revealed more mature collagen (yellow) at the connective tissue sites than in the diabetic wounds, where neo-synthesized collagen (light bluish-green) seemed to dominate, indicating delayed wound healing. Histologic scoring revealed a tendency toward reduced formation of granulation tissue among the diabetic animals, especially in the b6 ) ⁄ ) mice, but statistical significance could not be achieved (Fig. 4B) . As a control experiment, we localized the presence ⁄ absence of the avb6 integrin at the wound edge sites by immunohistochemistry (Fig. 5) . The keratinocytes at the wound edges of WT animals stained positive for the avb6 integrin in both untreated and STZtreated mice. The b6
) ⁄ ) mice all stained negative apart from some background staining of hair follicles in the unwounded normal skin.
Glycation of FN impairs HaCaT cell spreading in vitro
We hypothesized that the delayed wound re-epithelialization could be associated with aberrant cross-linking to important integrinbinding ligands of the wound bed matrix because of the formation of AGEs. Therefore, we performed an in vitro spreading assay using human HaCaT keratinocytes seeded on the integrin-binding ligand FN. For these experiments, we used FN that had been treated with MG to generate AGEs to mimic the diabetes-induced hyperglycemic effect on ECM tissue proteins.
Gel electrophoresis and Western blotting were used to verify the glycation of FN by MG as it has been reported in other studies (9, 35) . MG-treated (FN-MG) and untreated FN showed similar mobility in SDS-PAGE gels (Fig. 6A ), but Western blotting using antibodies with specificity for the MG-conjugated part of the FN-MG protein-sugar complex confirmed the reaction (Fig. 6B) . Importantly, glycated and native FN showed similar coating efficiency to ELISA plates used in the subsequent cell experiments (Fig. 6C) .
The spreading frequency of HaCaT keratinocytes was determined upon seeding the cells on FN vs FN-MG-coated substrates. The spreading of HaCaT cells on FN-MG substrate was significantly reduced compared with the FN substrate (Fig. 6D) . On substrates coated with 10 lg ⁄ mL of control FN, approximately 50% of HaCaT cells showed spreading, whereas twice the coating concentration for FN-MG was necessary to obtain the same spreading frequency (Fig. 6D) . In addition, a significantly slower HaCaT cell spreading was observed on mice treated with citrate buffer only (control) or 55mg ⁄ kg streptozotocin in citrate buffer (diabetic) at days 0, 5, and 10 after wounding. Wound closure rate in the control mice was similar compared with WT and b6 ) ⁄ ) mice, whereas a delay in wound closure could be observed for the diabetic WT and especially the diabetic b6 ) ⁄ ) mice. Scale bar: 10 mm. (B-F) Relative wound area change over time. Data show mean ± SEM per cent of wound area relative to wound size at day 0 within each group (n = 36-56 wounds per group). Statistical significance between the two groups at each time point was assessed by Student's t-test. *p < 0.05, **p < 0.01, ***p < 0.001. (Fig. 6E) . We then investigated whether HaCaT keratinocytes utilized the same integrin receptors for binding FN-MG and FN. Incubation of cells with function-blocking antibodies against av and b6 integrin subunits resulted in about 50% inhibition of cell spreading on both FN-MG and FN substrates (Fig. 6F) . Likewise, incubation with an antibody against the b1 integrin subunit resulted in about 60% inhibition of cell spreading on both substrates, and applying a combination of antibodies to av and b1 integrins resulted in more than 90% inhibition (Fig. 6F) . These results indicate that both av and b1 integrins can support HaCaT keratinocyte spreading on FN regardless of its glycation state.
FN-MG compared with FN in time course experiments
DISCUSSION
Diabetes mellitus constitutes a major clinical problem and is associated with many complications, including impaired wound healing. As re-epithelialization is a crucial step of tissue repair characterized by migrating wound edge keratinocytes over a provisional matrix to restore barrier function, we investigated the role of the putative cell adhesion receptor avb6 integrin in epidermal wound healing in a diabetic mouse model. The induction of hyperglycemia in rodents using repeated injections of 55 mg ⁄ kg of STZ mimics diabetes mellitus type I that is caused by a T-cell-mediated auto-immune reaction against the pancreatic islet b-cells (39, 40) . This approach results eventually in a chronic stage of hyperglycemia. It is different from the diabetic state caused by a single higher dose (160-250 mg ⁄ kg) of STZ, which induces an acute and transient state of diabetes characterized by direct cytotoxicity, DNA damage, and apoptosis among the pancreatic b-cells (41-43). Our observation of an increased frequency of premature deaths among the diabetic b6-knockout mice post-wounding may be due to the combination of a chronic hyperglycemia and a mildly exaggerated inflammation in the lungs and skin, which is associated with the b6-deficient phenotype (17) .
In other diabetic rodent models, wound healing studies are often performed using the leptin receptor-deficient db ⁄ db mouse, which mice treated with citrate buffer (control) and 55mg ⁄ kg streptozotocin in citrate buffer (diabetic). E, epithelium; GT, granulation tissue; CT, connective tissue; WC, wound crust. Dashed lines indicate epithelial gap distance. Scale bar: 1 mm. (B) Epithelial gap distances were measured from day 5 mid-wound H&E sections as the distance between epithelial tongues from all the four groups. Mann-Whitney U-test revealed overall significant differences between control and diabetic animals (p < 0.01), and also between diabetic WT and b6 ) ⁄ ) mice, respectively (p < 0.05). (C) Histology was scored from 1 (lowest) to 4 (highest) based on the degree of cellular invasion, GT formation, vascularity, and re-epithelialization. n = 10-12 sections (two sections per wound) from five to six mice per group. Scale bars in B and C show mean ± SD. **p < 0.01. represents a model for type II diabetes mellitus characterized by hyperglycemia, obesity, hyperinsulinemia, and impaired wound healing (44, 45) . The db ⁄ db mouse is genetically diabetic and thereby negates the need for STZ administration (46) . However, as our goal was to specifically assess the role of avb6 integrin in diabetic wound healing, we decided to use the wellestablished model of chemically induced type I diabetes mellitus by intraperitoneal administration of STZ (41) in b6 integrin-deficient mice. By this experimental approach, we successfully generated chronic hyperglycemia, which in these animals predisposes to multiple vascular complications and cutaneous dysfunctions such as impaired wound repair due to AGE formation similar to humans (47) .
Our quantitative analysis of clinical wound pictures revealed that the lack of b6 integrin did not cause any significant delay in wound healing among vehicle-treated (citrate buffer; control) mice, which is in accordance with previous studies performed on young and adult, female and male mice of the same genetic backgrounds (23, ) show similar dense and well-organized neosynthesized collagen fiber bundles (blue-green) in the granulation tissue (GT). Small amounts of mature collagen (yellow) appear near the epidermis (E) and at the wound edge (WE) proximal to the unwounded connective tissue (arrows) and clarified by magnified picture insets. STZ-treated diabetic mice show less formation of GT, especially in the case of the b6
group, and no mature collagen is observed in either WT or b6 ) ⁄ ) mice. Scale bars: 100 lm. (B) The degree of GT formation from five to six mice per group was scored by an ordinate scale (1) (2) (3) (4) according to the degree of density and organization of neo-synthesized collagen fiber bundles as low (1), medium (2), or high (3). Presence of mature collagen among well-granulated wounds yielded a score of 4. No statistical difference could be established, but a tendency toward reduced GT formation among the diabetic animals, especially the b6 ) ⁄ ) mice, was observed. Bars show mean ± SD, n = 10-12 sections (two sections per wound) from five to six wounds. mice treated with citrate buffer (control) and 55mg ⁄ kg citrate-buffered streptozotocin (diabetic). b6 ) ⁄ ) mice showed a complete lack of b6 integrin staining in all specimens examined, with the exception of limited background staining of hair follicles. In the WT mice, the immunoreactivity of b6 integrin was confined to the wound edge of the epithelium containing populations of proliferating and migrating keratinocytes. WE, wound edge; GT, granulation tissue; CT, connective tissue; HF, hair follicles. Scale bar: 200 lm. 24). However, in the diabetic mice, we observed a statistically significant delay in wound healing in the b6 ) ⁄ ) group from day 1 to day 3 postwounding (p < 0.05), suggesting that avb6 integrin might play a protective role in the re-epithelialization phase of diabetic wound repair. No histologic differences at day 5 postwounding were found between the non-diabetic WT and b6 ) ⁄ ) animals when comparing epithelial wound gaps, granulation tissue formation, and collagen deposition. However, among the diabetic animals, we observed a reduction in granulation tissue formation, complete absence of mature collagen deposition and a minor tendency toward reduced keratinocyte migration in the b6 ) ⁄ ) mice. Surprisingly, a recent study reported accelerated wound repair in b6 integrin-deficient mice in a dexamethasone (DEX)-impaired wound healing model (48) . DEX is a glucocorticoid steroid hormone used as an immunosuppressive drug with unfortunate side effects such as skin atrophy and impaired wound healing caused in part by dysregulation of TGF-b1 (49). Xie et al. observed increased proliferation of epidermal and hair follicle-associated keratinocytes in the DEX-treated b6
mice compared with DEX-treated WT animals, which was linked to a reduction in pro-inflammatory cytokines and TGF-b1 (48) . In the Data show mean ± SEM of three independent experiments, n = 4 (D-E) and n = 8 (F). The effect of integrin blocking accounted for 88% of the total variation (p < 0.001), whereas no statistical difference was observed between keratinocyte spreading on FN and FN-MG within the same anti-integrin antibody blocking. All keratinocyte spreading data (D-F) were evaluated by a two-way ANOVA with Bonferroni post-tests. **p < 0.01, ***p < 0.001. STZ-induced diabetes model, the delay in wound healing was mainly associated with initial epithelial migration to the wounds, rather than later stages of re-epithelialization that are more dependent on keratinocyte proliferation. Therefore, the re-epithelialization defect observed in STZ-treated b6 ) ⁄ ) mice compared with WT diabetic mice is most likely a result of keratinocyte migration impairment rather than proliferation as supported by reduced spreading on glycated FN.
As described previously, a prolonged state of hyperglycemia can lead to tissue damage through aberrant cross-linking of proteins in the ECM and their receptors because of the accumulation of AGEs (50) , which can potentially lead to impaired keratinocyte function during re-epithelialization. In this study, we generated glycated FN through reaction with MG, a reactive a-oxaloaldehyde derived from the glucose metabolism and one of the most potent AGEformers found in vitro (51) and in vivo (35) . Indeed, intraperitoneal administration of MG results in induced diabetes-like microvascular alterations and impaired wound healing in rats (52) , and MG glycation of provisional matrix constituent type I collagen inhibits keratinocyte migration and spreading, possibly through modification of the putative binding site of integrin a2b1 (53, 54) . We here demonstrated that keratinocyte spreading was significantly reduced in a time-and dose-dependent manner on MGglycated FN.
Functional inhibition of integrin receptors using specific blocking antibodies demonstrated that the utilization of integrin receptors that bind native FN was not changed by glycation of FN, suggesting that the reduced spreading on MG-glycated FN was caused by masking of the integrin-binding sites. Intriguingly, AGE modification of FN alters the putative tripeptidebinding site (arginine-glycine-aspartic acid, RGD) which is a ligand for a variety of integrins, including avb6 (18, 55) . It is possible, therefore, that AGE-induced alteration of the RGD sequence in FN may cause aberrant crosslinking to many potential integrin receptors, and thereby hamper keratinocyte function during the re-epithelialization phase of diabetic wound healing. Taken together, our data point to a protective role of avb6 integrin in early diabetic wound healing during the phase of re-epithelialization. Moreover, we have demonstrated reduced spreading frequency of human keratinocytes on glycated FN, which could play a role in diabetic wound repair.
